🇺🇸 FDA
Patent

US 8404244

Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies

granted A61KA61K2039/5258A61K2039/53

Quick answer

US patent 8404244 (Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/5258, A61K2039/53, A61K2039/55566, A61K2039/58